Format

Send to

Choose Destination
See comment in PubMed Commons below
Neurosurgery. 2013 Mar;72(3):332-9; discussion 339-40. doi: 10.1227/NEU.0b013e31827fcdc2.

Stereotactic radiosurgical salvage treatment for locally recurrent esthesioneuroblastoma.

Author information

1
Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota 55905, USA. vangompel.jamie@mayo.edu

Abstract

BACKGROUND:

Esthesioneuroblastoma (ENB) is a rare malignant neuroendocrine tumor considered to be radiation sensitive. Local recurrence may be treated in a variety of ways, including stereotactic radiosurgery (SRS); however, little information on its effectiveness is available.

OBJECTIVE:

To determine whether SRS is effective in providing local control for recurrent ENB.

METHODS:

This was a retrospective single-institution experience including 109 patients with ENB treated at the Mayo Clinic (1962-2009). Sixty-three patients presented with Kadish stage C disease, and 21 patients developed local recurrence. Of these 21 patients, 7 patients underwent SRS at our institution and an additional patient underwent SRS after transnasal biopsy. Therefore, a total of 8 patients are reported.

RESULTS:

The median age at time of local recurrence was 50 years. All patients had Kadish C disease at initial diagnosis. Six of 8 patients were found to have Hyams grade 3 disease; the remaining 2 patients had grade 2 disease. The median treatment volume was 8.4 cm (mean, 18.9 cm; range, 1.4-76.3 cm), and the median dose to the tumor margin was 15 Gy (mean, 14.4 ± 2.2 Gy; range, 10-18 Gy). Of the 16 treatments, 13 had adequate follow-up to assess treatment response, with 92% achieving local control over a median follow-up of 42 months from the time of SRS. Five lesions decreased in size, 7 lesions stabilized, and only 1 lesion had in-field progression. There were no documented complications secondary to SRS.

CONCLUSION:

SRS appears to be a reasonable and safe option for treatment of intracranial recurrence of ENB.

PMID:
23208068
DOI:
10.1227/NEU.0b013e31827fcdc2
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center